The rising prevalence of kratom use in the United States has led to increased encounters with individuals who consume kratom and those who develop Kratom Use Disorder (KUD) among healthcare professionals. This case series highlights the need for diverse treatment approaches tailored to the individual motivations for kratom consumption. Three cases are presented: one involving the progression from kratom use for energy to opioid-driven use with subsequent challenges in detoxification and transition to naltrexone necessitating buprenorphine low-dose induction for maintenance; another detailing successful inpatient detoxification using methadone and symptom-driven clonidine, followed by successful maintenance treatment with naltrexone; and a final case involving kratom consumption for pain and anxiety self-management by an individual without a history of addictive disorders, without meeting KUD criteria. These cases underscore the complexity of managing individuals who consume kratom as well as those who develop dependence, emphasizing the need for individualized treatment approaches considering various factors such as motivation for use, psychiatric comorbidities, and response to interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02791072.2024.2424278 | DOI Listing |
Molecules
November 2024
Department of Pharmacognosy, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Mitragynine is an "atypic opioid" analgesic with an alternative mechanism of action and a favorable side-effect profile. Our aim was to optimize the alkaloid extraction procedure from kratom leaves and to determine and isolate the most relevant compounds capable of penetrating the central nervous system. The PAMPA-BBB study revealed that mitragynine and its coalkaloids, speciociliatine, speciogynine, and paynantheine, possess excellent in vitro BBB permeability.
View Article and Find Full Text PDFJ Psychoactive Drugs
November 2024
Centre for Drug Research, Universiti Sains Malaysia, Minden, Penang, Malaysia.
J Psychoactive Drugs
November 2024
Psychiatry Department, Dartmouth's Geisel School of Medicine, Hanover, NH, USA.
The rising prevalence of kratom use in the United States has led to increased encounters with individuals who consume kratom and those who develop Kratom Use Disorder (KUD) among healthcare professionals. This case series highlights the need for diverse treatment approaches tailored to the individual motivations for kratom consumption. Three cases are presented: one involving the progression from kratom use for energy to opioid-driven use with subsequent challenges in detoxification and transition to naltrexone necessitating buprenorphine low-dose induction for maintenance; another detailing successful inpatient detoxification using methadone and symptom-driven clonidine, followed by successful maintenance treatment with naltrexone; and a final case involving kratom consumption for pain and anxiety self-management by an individual without a history of addictive disorders, without meeting KUD criteria.
View Article and Find Full Text PDFCutis
September 2024
Isha Gandhi is from the University of Minnesota Medical School, Twin Cities Campus, Minneapolis. Dr. Wang is from the Laboratory of Dermatopathology, Woodbury, New York. Dr. Fishman is from the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Am J Physiol Regul Integr Comp Physiol
December 2024
Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida, United States.
Kratom (), containing the primary alkaloid mitragynine, has emerged as an alternative self-treatment for opioid use disorder. Mitragynine binds numerous receptor types, including opioid receptors, which are known to modulate food consumption. However, the ability of acute mitragynine to modulate food consumption remains unknown.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!